GE as many know initially was working with hESC's from Geron ip, then Ips cells from Cellular Dynamics, and now back to hESC with BTX. HESC's look to be the gold standard.
Looked at the 5 yr. chart and seems your on the ball. ISSCR is huge and GE/ESI should have something concrete to present since they formed a partnership 7 mo ago.
June 24-27, 2015
International Society for Stem Cell
Research (ISSCR) Annual Meeting
ESI BIO – A Division of BioTime, Inc.
thanks for the insight clone. 2016 will be very exciting and $20 is very likely with GE products as well as the bladder, breast and lung cancer tests on the market.
$20 for mid 2016 and higher as the year goes on.
MRNA one of the few RNAI companies yet to propel above $2 range. I bought in after several recent key milestones. SMARTICLES continued clinical success. There delivery of next-gen drugs(RNAI/stem cells) is very lucrative and MRNA seems to have a unique and important platform with SMARTICLES.
I also think the recent securing of key RNAi ip is key to MRNA's success and would think this would soon lead to major partnerships, mergers or a possible buyout. Lastly I thought Marina's new anti-tumor/white blood cell news sounded interesting.
My 2 cents
August and Sept pop with investors buying in a month or two before these blockbuster products in 4th Quarter. Until then guessing it will coast. 4.50 seems like the bottom considering their subsidiary AST is $12.
ALAMEDA, Calif.--(BUSINESS WIRE)--May 19, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the presentation of positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed samples of a simple blood-based test designed to aid physicians in the early detection of lung cancer. The large, prospective clinical study was conducted by The Wistar Institute, an international leader in basic biomedical research. The test was developed in the laboratory of Louise Showe, PhD, professor in the Molecular and Cellular Oncogenesis program of The Wistar Institute's NCI-designated cancer center. Andrew Kossenkov, PhD, a senior member of Dr. Showe's laboratory and Managing Director of Wistar's Bioinformatics Facility, will present interim results from the study at the American Thoracic Society (ATS) International Conference during an oral presentation beginning at 2:45 PM MDT on Tuesday, May 19, 2015.
Long term but huge rev product. Important thing to remember is that BTX retinal cells are zeno(animal) free, ACTC(Ocata)'s product is not.